← Leaderboards
Christoph Geisler
Paratechs Corp.
$3,261,906
Attributed
$4,318,968
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $907.9K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,318,968 · 6
By mechanism
R44$3,257,276 · 3
R43$1,061,692 · 3
Top collaborators
- Donald L. Jarvis3 shared
- Angelika Fath-Goodin2 shared
Others in their field
Top investigators on “Small Business Innovation Research Grant”
- David Heimbrook · Leidos Biomedical Research, Inc.$122,677,088
- Praduman Jain · Vignet, Inc.$106,968,877
- Stephen Lev Hoffman · Sanaria, Inc.$37,771,680
- Eric Baer · Case Western Reserve University$37,136,000
- John B Buse · University Of North Carolina Chapel Hill$23,865,764
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
Research focus
Small Business Innovation Research GrantCellsDesignEngineeringCostCommercializationProductionInnovationProteinsRecombinant ProteinsMarketingPharmaceutical PreparationsGlycoproteinsEnzymesInsectaLettersCell LineBaculovirusesPolysaccharidesLifeTherapeutic ProteinPositioning AttributePropertyBiological
Grant awards (10)
Oxalate Biodegrading Probiotic for Kidney Stone Prevention$907,860
R44 · FY2025 · DK · contact PI
Oxalate Biodegrading Probiotic for Kidney Stone Prevention$834,533
R44 · FY2024 · DK · contact PI
Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones$54,965
R43 · FY2023 · DK · contact PI
Constitutive oxalate-biodegrading Bacillus subtilis for kidney stones$259,284
R43 · FY2022 · DK · contact PI
Glycoengineered insect cells for commercial biologics manufacturing$446,173
R44 · FY2016 · GM · contact PI
Glycoengineering insect cells for commercial recombinant glycoprotein production$296,812
R43 · FY2014 · GM · contact PI
Engineering cells for concurrent protein drug biosynthesis and polysialylation$148,202
R43 · FY2014 · GM · contact PI
Enhancing mammalian glycoprotein production in the baculovirus expression vector$497,092
R44 · FY2013 · GM
Glycoengineering insect cells for commercial recombinant glycoprotein production$302,429
R43 · FY2013 · GM · contact PI
Enhancing mammalian glycoprotein production in the baculovirus expression vector$571,618
R44 · FY2012 · GM